TransVivo

TransVivo, Inc. was a biotechnology company that developed a proprietary extracorporeal system for cell-based therapies, primarily targeting Type 1 Diabetes and organ transplant rejection. The company's core technology, the TransVivo system, utilized an immunoisolation device to house therapeutic cells like pancreatic islets, allowing them to function as a bio-artificial organ while protected from the patient's immune system. This approach was designed to provide a long-term solution for hormone or protein deficiencies without the requirement for systemic immunosuppressive drugs. While the company successfully initiated early clinical feasibility studies and demonstrated the potential of its bio-artificial pancreas platform, it has since ceased active operations.